Arca
Skip to content
Tools
Tools

Warning Letter to Reine Lifescience

Unspecified. See Reine Lifescience's company page or this site's inspections.

On May 9, 2018, FDA's CDER sent Reine Lifescience a warning letter citing data integrity, cleaning validation, method validation.

  • Letter date: May 9, 2018
  • Issued by: CDER
  • Closeout: —

The Letter

As posted on FDA.gov ↗; cited 21 CFR sections link to their page.

• a summary of method validation and verification studies for all analytical methods used for product release;

• a summary of the impact assessment for released batches;

• improved procedures regarding validation/verification requirements and updated analytical methods;

• a comprehensive, independent review of your laboratory practices, methods, equipment, and analyst competencies. Based on this review, provide a detailed corrective action and preventive action (CAPA) plan to fully remediate your laboratory system.

• a global CAPA plan as requested below under “Data Integrity Remediation.”

• provide a summary of your interim controls to prevent deletion and modification of data;

• define the roles and responsibilities of personnel who have access to analytical instruments and data;

• provide a standard operating procedure (SOP) that ensures that all quality control tests are performed by an analyst and receive second-tier review (e.g., by a manager) from a separate individual;

• detail the associated user privileges for each analytical system;

• provide a detailed summary of your procedural updates and associated training for user role assignment and controls; and

• provide detailed procedures for your review of audit trail data.

• scientific rationale for API, rinse, and swab sample specifications prior to performing cleaning validation;

• a summary of updates to your cleaning validation protocol to better incorporate conditions identified as worst case. This should include evaluating drugs that are of highest toxicity, drugs that are lowest solubility in their cleaning solvents, and swabbing of various equipment locations that are most difficult to clean.

• a summary of SOP that have been updated to ensure an appropriate program for verification and validation of cleaning procedures for new products, processes, and equipment.

Recent Letters Citing Data integrity

See them all

Record

Recipient
Mr. Amish Shah
FDA site ID (FEI)
3011543431

Tags are assigned by Arca from the letter's text. A closeout letter means FDA found the firm's corrections adequate; no closeout does not mean the issues are unresolved. FDA warning letters

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.